ArticleHuman genomics2025
Clinical utility of trio whole exome sequencing in fetuses with ultrasound anomalies.
Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Prenatal diagnosis of cardiac rhabdomyoma: implications for predicting tuberous sclerosis complex and guiding perinatal management.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2026Article
- Article
- Application of chromosomal microarray analysis and trio whole-exome sequencing in first-trimester prenatal diagnosis for high-risk pregnancies.BMC pregnancy and childbirth · 2026Article
- Genotype-phenotypic correlation in a Chinese patient with isolated lissencephaly sequence caused by 17p13.3p13.2 chromosomal microdeletion: a 6-year follow-up study.Frontiers in genetics · 2026Article
- Revisiting the Genetics of Hypophosphatasia.Journal of inherited metabolic disease · 2025Review
- Diagnostic performance of chromosomal microarray and whole exome sequencing in fetal structural anomalies: a single-center retrospective study.BMC pregnancy and childbirth · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUltrasound scanning anomalies in fetuses are a cause for concern and often necessitate further diagnostic procedures. This retrospective study evaluated the utility of trio whole exome sequencing (trio-WES) in the diagnosis of fetuses with ultrasound anomalies.
methodsWe included fetuses diagnosed with fetal ultrasound anomalies referred to the First Affiliated Hospital of Chongqing Medical University between November 2018 and July 2023. Fetal anomalies were classified into structural anomalies, dynamic anomalies, and soft markers. Karyotype analysis, chromosomal microarray analysis (CMA) or copy number variation sequencing (CNV-seq) and trio-WES were performed for the eligible cases. Perinatal outcomes were recorded and evaluated at postnatal follow-up.
resultsA total of 316 fetuses were included for the analysis, including 199 (63.0%) cases with structural abnormalities, 63 (19.9%) cases with dynamic abnormalities, and 54 (17.1%) fetuses with ultrasonic soft markers. The diagnostic yield of karyotyping and CMA/CNV-seq was 4.1% (13/316), and Trio-WES achieved an additional diagnosis rate of 15.8% (50/316). Pathogenic or likely pathogenic alleles (P/LP) variants of 132 genes were identified in 125 (39.6%, 125/316) cases, and variant of uncertain significance (VUS) was detected in 81 samples (25.6%, 81/316). Ten cases (3.2%, 10/316,) were found to have pathogenic karyotype or CNVs in supplementary analysis of WES. Fetuses presenting musculoskeletal anomalies and multiple anomalies demonstrated highest diagnostic rates at 36.4% (8/22) and 36.1% (13/36), respectively. The diagnostic rate of fetuses with short femur was 20% (8/40), significantly higher than other ultrasonic soft markers. The modes of inheritance observed in patients with molecular diagnoses were autosomal dominant (AD) in 66.0% cases (33/50), autosomal recessive (AR) in 26.0% cases (13/50), and X-linked (XL) in 8.0% cases (4/50).
conclusionThe integration of CMA/CNV-seq with trio-WES, alongside prenatal ultrasound scanning, holds the promise of significantly enriching our ability to decipher fetal phenotypes. This tripartite approach stands to revolutionize the diagnostic process, offering a more comprehensive and nuanced understanding of the underlying genetic architecture that underpins prenatal anomalies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.